rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Femasys Inc.

FEMY · Nasdaq

Health CareMedical DevicesNot moving yet

FEMY stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 67.8% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$268K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
17 (-14)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$258KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months0
Buyers · sellers5 · 0
WhoDidSharesTraded
Kathy Lee-SepsickChief Executive Officerbought15,625at $3.207 Aug 2026filed 11 Aug 2026
Dov ElefantChief Financial Officerbought15,625at $3.207 Aug 2026filed 11 Aug 2026
John Charles CanningChief Operating Officerbought4,375at $3.207 Aug 2026filed 11 Aug 2026
Jeremy Alexander SiposChief Technology Officerbought3,125at $3.207 Aug 2026filed 11 Aug 2026
Jeffrey Gerald MifekChief Clinical-Medical Affairsbought3,125at $3.207 Aug 2026filed 11 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders17-14 on the quarter
New · exited6 · 20
Reported value$8.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Dauntless Investment Group, LLCreduced · filed 13 Aug 20261,867,987$7.8M-4,165,043−69.0%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 202662,232$260K+62,232
JANE STREET GROUP, LLCadded · filed 14 Aug 202652,511$219K+20,235+62.7%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202630,920$129K-590,446−95.0%
UBS Group AGreduced · filed 13 Aug 202618,777$78K-43,152−69.7%
CITADEL ADVISORS LLCnew · filed 14 Aug 202616,921$71K+16,921
VANGUARD FIDUCIARY TRUST COnew · filed 13 Aug 202612,492$52K+12,492
OSAIC HOLDINGS, INC.reduced · filed 14 Aug 20262,397$10K-45,567−95.0%
BlackRock, Inc.reduced · filed 7 Aug 20261,784$7,457-176,717−99.0%
IFP Advisors, Incadded · filed 20 Jul 20261,050$515+50+5.0%
31 Mar 2023 – 30 Jun 2026
152433Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Dov Elefant Company insiderChief Financial Officer · last 7 Aug 20261 · 0
Jeffrey Gerald Mifek Company insiderChief Clinical-Medical Affairs · last 7 Aug 20261 · 0
Jeremy Alexander Sipos Company insiderChief Technology Officer · last 7 Aug 20261 · 0
John Charles Canning Company insiderChief Operating Officer · last 7 Aug 20261 · 0
Kathy Lee-Sepsick Company insiderChief Executive Officer · last 7 Aug 20261 · 0
Alistair Milnes Company insiderDirector · last 24 Jun 20260 · 0
Charles Larsen Company insiderDirector · last 24 Jun 20261 · 0
Edward R. Uzialko Company insiderDirector · last 24 Jun 20261 · 0
Kenneth D. Eichenbaum Company insiderDirector · last 24 Jun 20260 · 0
Joshua Silverman Company insiderDirector · last 25 Jun 20250 · 0
Kelley Stinson Nicholas Company insiderChief Commercial Officer · last 23 Jun 20250 · 0
Daniel Scott Currie Company insiderChief Operating Officer · last 2 Jun 20250 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202562.0%
Operating profit marginFY 2025 · to 31 Dec 2025-767%
Free cash flow marginFY 2025 · to 31 Dec 2025-838%
Return on capital employedFY 2025 · to 31 Dec 2025-103%
Research spendFY 2025 · to 31 Dec 2025330%
Share count trendFY 2025 · to 30 Mar 20261.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$9.3M
Free cash flowFY 2025 · to 31 Dec 2025−$19.2M

Analyst forecasts

No analyst forecasts yet.